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The pharmacological roles of the neuropeptide neurotensin through its three known recep-
tors are various and complex. Neurotensin is involved in several important biological
functions including analgesia and hypothermia in the central nervous system and also food
intake and glucose homeostasis in the periphery.This review focuses on recent works deal-
ing with molecular mechanisms regulating blood glucose level and insulin secretion upon
neurotensin action. Investigations on crucial cellular components involved in the protective
effect of the peptide on beta cells are also detailed.The role of xenin, a neurotensin-related
peptide, on the regulation of insulin release by glucose-dependent insulinotropic polypep-
tide is summarized. The last section comments on the future research areas which should
be developed to address the function of new effectors of the neurotensinergic system in
the endocrine pancreas.
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INTRODUCTION
The endogenous peptide neurotensin (NT) was discovered in
1973 in bovine hypothalami by Carraway and Leeman (1973)
for its ability to induce vasodilatation. This property added to
its cerebral expression indicated that the peptide could fulﬁll a
dual function, as a neurotransmitter/neuromodulator in the cen-
tral nervous system, and as a hormone in the periphery. NT is
expressed in the central nervous system where it is located in
neuronal synaptic vesicles (Uhl and Snyder, 1976; Bayer et al.,
1991) and in the gastrointestinal tract (Goedert and Emson, 1983)
in neuroendocrine cells (Atoji et al., 1995). NT is synthesized
from a precursor following excision by prohormone convertases
(Kitabgi, 2006).
The pharmacological and physiological effects of NT are trig-
gered following its interaction, depending on the tissue or the cell
type, by three known receptors (NTSRs). Two of them, NTSR1
and NTSR2, are classical neuropeptide receptors coupled to G-
proteins (GPCR) bearing seven transmembrane domains (Vincent
et al., 1999; Myers et al., 2009). The third one, NTSR3 also called
sortilin (Petersen et al., 1997; Mazella et al., 1998), is a type I
receptor with a single transmembrane domain, non-coupled to
G-proteins, which belongs to the Vps10p containing domain
receptor family (Mazella, 2001; Hermey, 2009). The heterogeneity
in the structure of NTSRs, added to their ability to form homo
and/or heterodimers (Martin et al., 2002; Beraud-Dufour et al.,
2009; Hwang et al., 2010), underlines the complexity to study
the neurotensinergic system both in the brain and in peripheral
tissues.
In the central nervous system, the effects of NT include
the interaction of the peptide with the dopaminergic system
(Studler et al., 1988) and its ability to induce opioid-independent
analgesia (Dubuc et al., 1999) and hypothermia (Popp et al.,
2007). The latter property could allow the use of bioavail-
able NT analogs to reduce the risk of brain damage following
hypoxia (Choi et al., 2012). The anti-psychotic and hypother-
mia effects of NT are mediated through NTSR1 (Dobner,
2005; Hadden et al., 2005; Choi et al., 2012), whereas NT-
induced analgesia involves both NTSR1 and NTSR2 (Dubuc
et al., 1999; Smith et al., 2012). NTSR3/sortilin is responsible
for the migration and the release of cytokines and chemokines
from microglial cells induced by NT (Martin et al., 2003; Dicou
et al., 2004).
At the neuroendocrine point of view, the actions of NT as
a regulator of anterior pituitary secretions and food intake has
been recently well reviewed (Rostene and Alexander, 1997; Sto-
lakis et al., 2010; Kalafatakis and Triantafyllou, 2011). For this
reason, these sections will be only summarized at the beginning
of this review focusing essentially on the role of NT in the control
of glucose homeostasis. The roles of NT in insulin regulation and
pancreatic cell growth have been initiated by several works (Kaneto
et al., 1978; Dolais-Kitabgi et al., 1979; Wood et al., 1988). How-
ever, molecular characterization of the signaling pathways and the
receptors involved in both pancreatic cell proliferation and beta
cell secretion have been only recently investigated (Guha et al.,
2003; Friess et al., 2003; Kisfalvi et al., 2005; Elghazi et al., 2006;
Beraud-Dufour et al., 2010).
In addition, we will present the role of a NT-related peptide,
named xenin, in the regulation of glucose homeostasis. Xenin
is a peptide of 25 amino acids discovered in 1992 (Feurle et al.,
1992), and which is synthesized from a precursor of 35 amino
acids (Hamscher et al., 1996). Intriguingly, the sequence of this
precursor is 100% identical to the N-terminal sequence of the
mammalian coat protein α (α-COP; Chow and Quek, 1996), a
cytoplasmic protein which cannot be released.
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NT AND METABOLISM
The energetic balance is regulated by the control of satiety, a
domain which has evoluted following the discovery of leptin. This
peptide is secreted by adipocytes and acts as a hormone directly
on speciﬁc hypothalamic areas involved in the control of food
intake (Jequier, 2002). Interestingly, several works reported that
the effects of leptin are controlled by NT expressing neurons (Cui
et al., 2006). Indeed, the anorectic effect of leptin is impaired
in NTSR1-deﬁcient mice (Kim et al., 2008), suggesting that the
complex NT-NTSR1 is crucial for the action of leptin. More-
over, Leinninger et al. (2011) published an elegant demonstration
showing that the action of leptin via NT neurons controls orexin
release, the mesolimbic dopamine system and energy balance. In
conclusion, the control of food intake is mediated by leptin on NT
expressing neurons through NTSR1.
The other important aspect of the neurotensinergic system in
the periphery concerns the control of nutrient absorption. Rapidly
following its discovery, it was observed that the level of circulating
NT increased several minutes after a meal, and this increase was
more important when the food was enriched with fatty acid (Lee-
man and Carraway, 1982). Recently, Gui and Carraway (2001)
completed this observation by demonstrating that NT acts as a
hormone released from intestine following ingestion of fat, and
facilitates lipid digestion by stimulating pancreatic secretion. It
was also demonstrated that NT enhanced taurocholate absorption
from proximal rat small intestine indicating a role in the regula-
tion of enterohepatic circulation. This effect is largely mediated by
the release of mast cell mediators, and is regulated by NO (Gui and
Carraway, 2004). In conclusion, NT acting as a neurotransmitter
or as a hormone, regulates food intake (satiety) and lipids absorp-
tion indicating a general role for NT in the regulation of energy
balance and in the control of homeostasis.
NT AND PANCREAS
Immunoreactive-NT (IR-NT)has beendetected inplasma extracts
and plasma IR-NT elevation occurs in response to nutrient stimuli
(Rosell and Rokaeus, 1979). This suggested that NT may inﬂuence
pancreatic regulation by a hormonal mechanism. IR-NT is present
in the pancreas (Fernstrom et al., 1981) and a direct (paracrine)
inﬂuence on islet hormone secretion was suggested. The presence
of NT in the circulation and in the pancreas can be correlated
to its effects on insulin and glucagon release (Dolais-Kitabgi et al.,
1979) andon the growthof ductal adenocarcinomaof the pancreas
(Reubi et al., 1998). Actually, we know that the action of NTon islet
secretion is the consequence of the expression of the three NTSRs
in normal endocrine pancreas (Beraud-Dufour et al., 2010). By
contrast, NTSRs are not expressed in normal exocrine pancreas,
their expression being linked with the development of tumors
(Kitabgi, 2002; Myers et al., 2009).
Administration of NT increased pancreatic weight, DNA,RNA,
and protein contents as well as lipase concentration (Feurle et al.,
1987). The proliferative effect of NT on the pancreas has been also
demonstrated by Wood et al. (1988). The role of NT and other
gastrointestinal hormones like cholecystokinin or gastrin releasing
peptide in the growth of normal and neoplastic tissues, including
pancreas, has been well documented in a review article (Thomas
et al., 2003).
NT AND PANCREATIC CANCER GROWTH
It is now well established that NT receptors are expressed in
exocrine pancreatic tumors and chronic pancreatitis whereas these
receptors were not found in normal exocrine pancreatic tissues
(Reubi et al., 1998; Wang et al., 2000). Numerous studies have
demonstrated that NT stimulates mitogenic signaling pathways
and DNA synthesis in human pancreatic cancer cell lines includ-
ing PANC-1 and MIA PaCa-2 cells (Herzig et al., 1999; Ehlers
et al., 2000; Ryder et al., 2001; Guha et al., 2002; Falciani et al.,
2010). These growth effects are mediated through NTSR1 stim-
ulation (Iwase et al., 1997). However, a recent study concluded
that NT-induced migration of pancreatic ductal adenocar-
cinoma cells in vitro occurs via NTSR3/sortilin pathways (Mija-
tovic et al., 2007).
NT AND ENDOCRINE PANCREAS
The ﬁrst in vivo observation that NT displayed a role in glucose
homeostasis was performed in the rat where the peptide pro-
duced hypoinsulinemia and consequently hyperglycemia (Brown
and Vale, 1976). Then after, a more detailed work performed on
rat islets of Langerhans demonstrated that NT regulates endocrine
pancreatic hormones release (Dolais-Kitabgi et al., 1979). In this
study, NT was shown to stimulate insulin and glucagon release at
low glucose concentration whereas at high glucose or arginine lev-
els, NT inhibits the release of both peptides. However, in another
study performed on isolated neonatal rat islets, NT was unable
to alter insulin secretion under high glucose concentration (Fuji-
moto, 1981). This result may be due to the absence of some NTSRs
at this stage of development (Zsurger et al., 1992). The involvement
of NT in the regulation of glucose homeostasis has been conﬁrmed
in a clinical study dealing with healthy elderly and young subjects.
It was demonstrated that in addition to hyperinsulinemia and
hypergastrinemia, the postprandial responses for NT were signiﬁ-
cantly higher in the aged subjects (Arnalich et al., 1990). However,
no abnormality in the content of NT was detected in human
diabetes, as demonstrated in insulin-dependent diabetic patients
and in lean or obese non-insulin-dependent diabetic patients
(Service et al., 1986).
MOLECULAR MECHANISMS OF NT ACTION ON BETA CELLS
PROTECTION OF BETA CELLS
Although there is a lack of evidence for a role of NT in dia-
betes, there are convincing data for its implication in glucose
homeostasis. Surprisingly, no more important studies have been
carried out to identify the NT receptor(s) involved in the effects
observed. Only very recently our studies investigated themolecular
mechanisms involved in the activation of the signaling path-
ways responsible for NT functions in cultured beta cells. We
ﬁrst demonstrated that all the identiﬁed NTSRs are expressed in
murine Langerhans islets and in beta cell lines (Coppola et al.,
2008; Beraud-Dufour et al., 2009). We demonstrated that NT
efﬁciently protects beta cells from external cytotoxic agents (stau-
rosporine, IL-1beta) through the PI3 kinase pathway (Coppola
et al., 2008; Figure 1). The NTSR2 partial agonist levocabas-
tine exerts a protective effect similar to that of NT whereas the
NTSR1 antagonist SR48692 is unable to block the effect of NT
suggesting the predominant involvement of the NTSR2 in the
Frontiers in Endocrinology | Neuroendocrine Science November 2012 | Volume 3 | Article 143 | 2
“fendo-03-00143” — 2012/11/23 — 18:50 — page 3 — #3
Mazella et al. Neurotensin control of glucose homeostasis
protective action of NT on beta cells. Moreover, we showed that
this effect is mediated by NTSR2 via the protein complex formed
between the GPCR NTSR2 and the type I receptor NTSR3/sortilin
(Beraud-Dufour et al., 2009; Figure 1). In this case, the role of
NTSR3/sortilin has been postulated to direct NTSR2 to its func-
tional plasma membrane compartment as shown for NTSR1 in
HT29 cells (Martin et al., 2002) and for the potassium channel
TREK-1 in neurons (Mazella et al., 2010).
The protective action of NT on beta cells is of importance
since in diabetes beta cell death is generally the consequence of
prolonged hyperglycemia and/or hyperlipidemia. Therefore tak-
ing into account that NT is released in the circulation after a
meal, in particular after lipid absorption, the neurotensinergic
system may save endocrine pancreas as previously demonstrated
for glucagon-like peptide 1 (for review Desgraz et al., 2011).
REGULATION OF INSULIN SECRETION
From experiments carried out on rat beta cell lines, we con-
ﬁrmed the dual action of NT, which is able to increase insulin
secretion at low glucose concentration and also to decrease
the glucose-induced insulin release (Dolais-Kitabgi et al., 1979;
Beraud-Dufour et al., 2010). At the cellular level NT, as well as
the NTSR2 selective ligand levocabastine, rapidly and transiently
increases the intracellular concentration of calcium in Ins1-E cell
line. NT-evoked calcium regulation involves PKC and the translo-
cation of PKCα and PKCε to the plasma membrane. A similar
response is obtained with levocabastine, indicating that NTSR2
triggers the effect of NT both on insulin secretion and calcium
concentration (Figure 1). This result is in total agreement with
a study from 1978 in which the hyperglycemia action of NT was
shown to be mediated through histamine since blockers of both
H1 and H2 histamine receptors were able to inhibit the effect of
NT (Nagai and Frohman, 1978). Indeed, it is important to remem-
ber that levocabastine, originally developed against H1 histamine
receptors (Kitabgi et al., 1987), is a selective ligand of NTSR2
(Chalon et al., 1996; Mazella et al., 1996). Moreover, we demon-
strated that the propeptide issued from the maturation of the
precursor form of NTSR3/sortilin (Munck Petersen et al., 1999)
triggers an increase of intracellular calcium and insulin secre-
tion as observed for NT and levocabastine (Beraud-Dufour et al.,
2010). The propeptide acts as an antagonist of NTSR3/sortilin
(Martin et al., 2003), however it does not block the NT effect. This
FIGURE 1 | Neurotensin receptors signaling in beta cells.
Two G protein-coupled receptors, NTSR1 and NTSR2, and one type
I receptor, NTSR3, are expressed in beta cells. In one hand, the
binding of NT to the complex NTSR2/NTSR3 leads to the stimulation of
phospholipase C to enhance the intracellular concentration of calcium
responsible for the secretion of insulin. In a second hand, the interaction
of NT with the same receptor complex activates the PI3 kinase, resulting
in the phosphorylation of Akt to protect beta cells from the apoptosis
induced by cytotoxic external agents. Although NTSR1 is expressed
in beta cells, an unusual positioning or the absence of the receptor
at the plasma membrane may explain the absence of interaction with
NT. The propeptide (PE) which is released from the precursor form of
NTSR3 displays agonist activity to increase intracellular calcium
concentration.
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suggests that NTSR3/sortilin may be also involved, in combina-
tion with NTSR2, in the action of NT. We know that NTSR2 and
NTSR3/sortilin form heterodimers in these beta cells (Beraud-
Dufour et al., 2009). However, we do not know the exact role
of NTSR3 in this complex. NTSR3 may regulate the membrane
expression of NTSR2, as reported for NTSR1 (Martin et al., 2002)
and the two pore potassium channel TREK-1 (Mazella et al., 2010),
and so only NTSR2 selective ligand may activate the receptor com-
plex to trigger the effect. NTSR3/sortilin selective ligands (i.e., the
propeptide) may also contribute to the ﬁnal activation. Further
studies carried out on NTSR KO animal models would be crucial
for a better understanding of the role of each receptor on insulin
secretion.
Interestingly, xenin, a peptide related to NT (Feurle et al., 1992)
and co-secreted with glucose-dependent insulinotropic polypep-
tide (GIP) from intestinal K-cells (Anlauf et al., 2000), regulates
glucose homeostasis and potentiates the action of GIP on glucose-
mediated insulin release (Taylor et al., 2010; Wice et al., 2010).
Xenin enhances GIP-mediated insulin release by a mechanism
which does not involve direct action on beta cells. Rather, the
effect of xenin appears to bemediatedby activatingnon-ganglionic
cholinergic neurons that innervate islets (Wice et al., 2010). The
effect of xenin in combination with molecules regulating insulin
secretion rates is observed only in humans with normal or
impaired glucose tolerance but not with type 2 diabetes (Wice
et al., 2012). However, although xenin has been suggested to inter-
act withNTSR1 in guinea pig enteral smoothmuscles (Feurle et al.,
2002) and in the effect of the peptide in food intake (Kim and
Mizuno, 2010), evidence for non-neurotensin receptor-mediated
effects of xenin has also been documented in rat intestine (Heuser
et al., 2002). In the absence of demonstration that xenin interacts
directly with one of the three known NTSRs, the effects of this
peptide could be mediated by a system which is, at least partly,
independent from the neurotensinergic system for the regulation
of insulin secretion.
CONCLUSION AND FUTURE
From the overall data obtained on pancreatic beta cells and islets,
it is clear that although the three NT receptors are expressed, the
effects of NT involve both NTSR2 and NTSR3/sortilin but not
NTSR1 (Figure 1). This is intriguing since the majority of the
actions of NT both in the brain and in the periphery involves,
at least partly, NTSR1, a receptor which was always shown to be
expressed and functional at the plasma membrane of NT target
cells. One possible explanation of its lack of implication in beta
cells could be that although NTSR1 is detected by PCR and West-
ern blot, the protein is absent or not correctly sorted at the plasma
membrane. One of the arguments in favor of this hypothesis is that
the binding of iodinated NT measured on membrane homogenate
from beta cells is totally displaced by levocabastine (personal
observation). Unfortunately, in the absence of efﬁcient antibodies
directed against NTSR1 for immunocytochemistry, sub-cellular
localization of protein expression appears difﬁcult to be correctly
investigated.
On another hand, the presence of NTSR3/sortilin, as well as
the effect of the propeptide on the intracellular concentration
of calcium in beta cells, may be also of importance. Indeed,
the role of NTSR3/sortilin as a sorting protein and its ability
to be translocated to the plasma membrane upon activation by
NT (Chabry et al., 1993; Navarro et al., 2001) where the propep-
tide can be released could serve as a new system of regulation
of endocrine hormone release. Moreover, NTSR3/sortilin is also
expressed on adipocytes and skeletal muscles, targets of insulin, in
which its translocation to the cell surface has been also demon-
strated (Lin et al., 1997; Shi and Kandror, 2007). Here again,
the propeptide can be released in the circulation and then can
FIGURE 2 | Regulation loop between insulin secreting and
target cells. In beta cells, insulin can be secreted in the circulation
by glucose, NT and also by the propeptide (PE) likely through its interaction
with NTSR2 or the potassium channel TREK-1 through NTSR3. In insulin
target cells, the activation of insulin receptor by insulin leads to the
Akt-dependent translocation of Glut4/NTSR3/sortilin containing vesicles
to the plasma membrane where the propeptide can be released in the
circulation. This loop of regulation between insulin secreting and
insulin target cells is likely involved in ﬁne tuning of glucose
homeostasis.
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regulate by feedback the secretion of insulin by interacting with
NTSR3/sortilin and TREK-1 (Figure 2). Taken together, these
observations reﬁne the regulation scheme of glucose homeosta-
sis through NT and its receptors and will lead to novel research
areas with new components and new functions like the propeptide
release and action.
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